Sandoz to commercialise opioid induced constipation tablet in EUAs it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi Share XSandoz to commercialise opioid induced constipation tablet in EUhttps://pharmaphorum.com/news/sandoz-to-commercialise-opioid-induced-constipation-tablet-in-eu/
Indivior stung by fraud charges over US marketingShares in UK drugmaker Indivior have gone into freefall after it was charged by the US Department of Share XIndivior stung by fraud charges over US marketinghttps://pharmaphorum.com/news/indivior-stung-by-fraud-charges-over-us-marketing/
Drug middlemen point finger at pharma in US pricing debateThe so-called ‘middlemen’ in the US pharma supply chain have blamed big pharma for skyrocketing drug prices in Share XDrug middlemen point finger at pharma in US pricing debatehttps://pharmaphorum.com/news/drug-middlemen-point-finger-at-pharma-in-us-pricing-debate/
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced Share XAZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancerhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/
At long last, Amgen/UCB score FDA okay for EvenityAmgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down Share XAt long last, Amgen/UCB score FDA okay for Evenityhttps://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/
Zogenix slumps after FDA refuses epilepsy drug fileZogenix’s only drug candidate is facing a long delay after the FDA refused to accept its marketing application, Share XZogenix slumps after FDA refuses epilepsy drug filehttps://pharmaphorum.com/news/zogenix-slumps-after-fda-refuses-epilepsy-drug-file/
ViiV hopes for blockbuster with HIV drug combo approvalThe FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for Share XViiV hopes for blockbuster with HIV drug combo approvalhttps://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/
Scotland backs Aimovig for migraine after NICE says noPeople suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig Share XScotland backs Aimovig for migraine after NICE says nohttps://pharmaphorum.com/news/scotland-backs-aimovig-for-migraine-after-nice-says-no/
Celgene files potential blockbuster luspaterceptCelgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up Share XCelgene files potential blockbuster luspatercepthttps://pharmaphorum.com/news/celgene-files-potential-blockbuster-luspatercept/
US drug cost body calls for SMA drug price cutsA US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular Share XUS drug cost body calls for SMA drug price cutshttps://pharmaphorum.com/news/us-drug-cost-body-calls-for-sma-drug-price-cuts/
NICE backs funding for MSD’s diabetes drug SteglatroNICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro Share XNICE backs funding for MSD’s diabetes drug Steglatrohttps://pharmaphorum.com/news/nice-backs-funding-for-msds-diabetes-drug-steglatro/
Health secretary hints at ‘constructive’ talks over CF drugsHealth secretary Matt Hancock has offered hope to thousands of people in the UK who have been denied Share XHealth secretary hints at ‘constructive’ talks over CF drugshttps://pharmaphorum.com/news/health-secretary-hancock-hints-at-constructive-talks-vertex/
Sanofi may airlift medicines into UK after BrexitFrance’s Sanofi has said it may fly supplies of flu vaccine into the UK if Brexit causes travel Share XSanofi may airlift medicines into UK after Brexithttps://pharmaphorum.com/news/sanofi-may-airlift-medicines-into-uk-after-brexit/
Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Acadia faces US federal probe into Nuplazid marketingAcadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into Share XAcadia faces US federal probe into Nuplazid marketinghttps://pharmaphorum.com/news/acadia-faces-us-federal-probe-into-nuplazid-marketing/
Vertex CEO hints at ‘new ideas’ to bring Orkambi to UK patientsVertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the Share XVertex CEO hints at ‘new ideas’ to bring Orkambi to UK patientshttps://pharmaphorum.com/news/vertex-ceo-hints-at-new-ideas-to-bring-orkambi-to-uk-patients/
FDA approves Janssen’s ketamine-based nasal antidepressantThe FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment Share XFDA approves Janssen’s ketamine-based nasal antidepressanthttps://pharmaphorum.com/news/fda-approves-janssens-ketamine-based-nasal-antidepressant/
